Evaluation of Serum CA 125 Levels in the Monitoring of Ovarian Cancer

Overview

Journal Am J Obstet Gynecol

Publisher Elsevier

Specialty Gynecology & Obstetrics

Date 1987 Jul 1

PMID 2440307

Citations 19

Authors

I B Vergote

O P Bormer

V M Abeler

Affiliations

Soon will be listed here.

Abstract

Serum CA 125 levels were evaluated in 227 patients with ovarian cancer. CA 125 levels were elevated in 86% of the patients. All histologic types, including mucinous tumors, were associated with raised CA 125 levels. There was a positive correlation with tumor burden and an inverse correlation with degree of differentiation. In patients undergoing radical operation an elevated CA 125 level was a bad prognostic index. Serial CA 125 measurements were assessable in 112 patients undergoing chemotherapy. Rising or falling levels correlated with disease in 92% of the cases. The CA 125 level increased before clinical progression with a median lead time of 3 months. Only patients who showed objective response to chemotherapy had a decrease in antigen levels of greater than or equal to 30% 4 weeks after the first course of chemotherapy and a normalization of CA 125 levels 3 months after initiation of chemotherapy. Rising levels were always associated with progression. These data suggest that CA 125 may aid in early identification of nonresponders. However, a normal CA 125 level does not exclude the presence of disease.

Citing Articles

Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.

Hunt A, Bateman N, Barakat W, Makohon-Moore S, Hood B, Conrads K iScience. 2021; 24(7):102757.

PMID: 34278265 PMC: 8264160. DOI: 10.1016/j.isci.2021.102757.

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.

Matte I, Garde-Granger P, Bessette P, Piche A BMC Cancer. 2019; 19(1):406.

PMID: 31039761 PMC: 6492407. DOI: 10.1186/s12885-019-5611-7.

Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.

Matte I, Garde-Granger P, Bessette P, Piche A Am J Cancer Res. 2019; 9(1):160-170.

PMID: 30755819 PMC: 6356915.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.

Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C BMC Cancer. 2015; 15:492.

PMID: 26122176 PMC: 4486134. DOI: 10.1186/s12885-015-1511-7.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

Giannakouros P, Comamala M, Matte I, Rancourt C, Piche A Am J Cancer Res. 2015; 5(1):219-30.

PMID: 25628932 PMC: 4300699.